Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena | Zendy

Lucia Vietri | Zendy; Paolo Cameli | Zendy; Marco Perruzza | Zendy; Behar Cekorja | Zendy; Laura Bergantini | Zendy; Miriana d’Alessandro | Zendy; Rosa Metella Refini | Zendy; Maria Pieroni | Zendy; Antonella Fossi | Zendy; David Bennett | Zendy; Marco Spalletti | Zendy; Maria Antonietta Mazzei | Zendy; Piersante Sestini | Zendy; Paola Rottoli | Zendy; Elena Bargagli | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena

Author(s) -

Lucia Vietri,

Paolo Cameli,

Marco Perruzza,

Behar Cekorja,

Laura Bergantini,

Miriana d’Alessandro,

Rosa Metella Refini,

Maria Pieroni,

Antonella Fossi,

David Bennett,

Marco Spalletti,

Maria Antonietta Mazzei,

Piersante Sestini,

Paola Rottoli,

Elena Bargagli

Publication year - 2020

Publication title -

therapeutic advances in respiratory disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.022

H-Index - 37

eISSN - 1753-4666

pISSN - 1753-4658

DOI - 10.1177/1753466620906326

Subject(s) - pirfenidone , medicine , idiopathic pulmonary fibrosis , vital capacity , adverse effect , interstitial lung disease , pulmonary function testing , surgery , discontinuation , lung , diffusing capacity , lung function

Our findings confirm the efficacy of pirfenidone in reducing functional progression of IPF and its excellent safety profile in a real-life setting. This study, designed on a long-term follow up, contributes to the growing evidence on safety, tolerability and efficacy of pirfenidone in IPF.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research